Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F, Hsu Ms S, Lum F, Gordon LK
Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Immunotherapy; Ipilimumab; Registries; Uveitis, Anterior
Academies and Institutes; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Electronic Health Records; Female; Humans; Immune Checkpoint Inhibitors; Incidence; Male; Middle Aged; Ophthalmology; Programmed Cell Death 1 Receptor; Retrospective Studies; United States; Young Adult
Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F, Hsu Ms S, Lum F, Gordon LK. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2021 06; 128(6):910-919.
Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Charles R. Drew University of Medicine and Science